Innate Pharma (IPHA) Common Equity (2017 - 2025)

Innate Pharma has reported Common Equity for 9 years, with the latest figure at -$25.3 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 367.63% year-over-year to -$25.3 million; the trailing twelve-month figure through Dec 2025 stood at -$25.3 million (down 367.63% YoY), and the FY2025 full-year result was -$25.3 million, down 367.63% from the prior year.
• Common Equity for Q4 2025 stood at -$25.3 million, down from $9.4 million in the prior quarter.
• The five-year high for Common Equity was $122.9 million in Q4 2021, with the low at -$25.3 million in Q4 2025.
• Historically, Common Equity has averaged $43.6 million across 5 years, with a median of $55.2 million in 2022.
• Annual changes were most pronounced in 2023 — Common Equity rose 1.08% — and 2025, when it plunged 367.63%.
• Innate Pharma's Common Equity stood at $122.9 million in 2021, then slumped by 55.05% to $55.2 million in 2022, then increased by 1.08% to $55.8 million in 2023, then tumbled by 83.1% to $9.4 million in 2024, then slumped by 367.63% to -$25.3 million in 2025.
• The last three Common Equity figures came in at -$25.3 million (Q4 2025), $9.4 million (Q4 2024), and $55.8 million (Q4 2023), per Business Quant data.